Hong Kong Stock Exchange · Healthcare
Invest in Shenzhen Neptunus Interlong Bio-technique stock from India
Indian and foreign residents can buy Shenzhen Neptunus Interlong Bio-technique (8329) shares directly through Paasa.
By Paasa · Updated
Shenzhen Neptunus Interlong Bio-technique at a glance
- Price
- HK$0.09+HK$0.00 (1.08%)
- Market cap
- HK$157.73M
- Day range
- HK$0.09 – HK$0.09
- P/E
- -2.74
- Dividend yield
- None
- Volume
- 100.00K
- 1 month
- -16.81%
- 6 months
- -30.88%
- YTD
- -40.88%
- 1 year
- -36.49%
- 5 years
- -60.50%
Shenzhen Neptunus Interlong Bio-technique statements, FY2021–FY2025
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | CN¥972.0M | CN¥1.0B | CN¥1.1B | CN¥986.7M | CN¥838.8M |
| Gross profit | CN¥287.2M | CN¥328.0M | CN¥439.2M | CN¥444.1M | CN¥368.1M |
| Operating income | −CN¥44.4M | CN¥34.7M | CN¥36.2M | CN¥89.3M | CN¥17.9M |
| Net income | −CN¥40.7M | CN¥25.0M | CN¥24.1M | CN¥54.3M | CN¥36.0M |
| Earnings per share | −CN¥0.02 | CN¥0.01 | CN¥0.01 | CN¥0.03 | CN¥0.02 |
| EBITDA | CN¥48.1M | CN¥62.9M | CN¥69.9M | CN¥125.2M | CN¥74.0M |
| Total assets | CN¥1.1B | CN¥1.4B | CN¥1.4B | CN¥1.4B | CN¥1.3B |
| Total debt | CN¥73.0M | CN¥105.4M | CN¥89.7M | CN¥92.7M | CN¥105.7M |
| Cash and short-term investments | CN¥209.4M | CN¥283.4M | CN¥382.2M | CN¥350.1M | CN¥311.1M |
| Shareholders' equity | CN¥647.7M | CN¥933.2M | CN¥908.2M | CN¥884.0M | CN¥829.7M |
| Operating cash flow | CN¥139.6M | CN¥24.4M | CN¥53.7M | CN¥61.2M | −CN¥69.9M |
| Free cash flow | CN¥125.0M | CN¥2.2M | CN¥38.3M | CN¥41.5M | −CN¥85.0M |
| Capital expenditure | −CN¥14.6M | −CN¥22.2M | −CN¥15.4M | −CN¥19.7M | −CN¥15.1M |
Fiscal years as reported, the latest ending 31 Dec 2025. Figures in CNY; a dash means the provider reported nothing for that line.
Peer comparison
| Company | Ticker | Price | Market cap |
|---|---|---|---|
| Tianda Pharmaceuticals | 0455.HK | HK$0.12 | HK$260.16M |
| Regent Pacific | 0575.HK | HK$0.82 | HK$239.29M |
| Tycoon | 3390.HK | HK$0.25 | HK$221.71M |
| Extrawell Pharmaceutical | 0858.HK | HK$0.07 | HK$205.90M |
| Tai United | 0718.HK | HK$0.03 | HK$168.00M |
| Bamboos Health Care | 2293.HK | HK$0.38 | HK$152.18M |
| PuraPharm | 1498.HK | HK$0.26 | HK$136.44M |
| Joyzyme | 8622.HK | HK$0.19 | HK$97.94M |
Peers as grouped by the data provider. This is not an investment recommendation.
How to invest in Shenzhen Neptunus Interlong Bio-technique from India
Step 1
Open your Paasa account
KYC takes a few minutes: PAN, Aadhaar and address proof. Your brokerage account is opened in your own name with Interactive Brokers.
Step 2
Add funds from your Indian bank account
Remit up to $250,000 a year under the RBI's Liberalised Remittance Scheme. Your bank converts the rupees to US dollars at its rate on the day you remit, and Interactive Brokers converts the dollars to HKD when you buy.
Step 3
Search 8329 and buy
Find Shenzhen Neptunus Interlong Bio-technique by name or by its ticker, 8329, and place your order. Many Hong Kong listings trade in board lots, so the smallest order is one lot rather than one share.
Why invest in Shenzhen Neptunus Interlong Bio-technique from India
What Shenzhen Neptunus Interlong Bio-technique does
Based in Shenzhen, People's Republic of China, Shenzhen Neptunus Interlong Bio-technique Company Limited and its subsidiaries are primarily engaged in the research, development, production, and sale of pharmaceuticals. The company also handles the procurement, distribution, and marketing of medicines and health food items, while undertaking research and development in biological technology. Shenzhen Neptunus Interlong Bio-technique operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector.
Paasa handles the paperwork
Investing abroad brings paperwork with it: remittance filings, capital gains reporting, foreign asset disclosure. Paasa prepares all of it for you. Your India-ready tax reports arrive at year end, ready to file.
Frequently asked questions
Can I buy Shenzhen Neptunus Interlong Bio-technique stock from India?
Yes. Indian residents and NRIs can buy Shenzhen Neptunus Interlong Bio-technique (8329) shares directly through Paasa. Shenzhen Neptunus Interlong Bio-technique is listed on the Hong Kong Stock Exchange, in the Drug Manufacturers - Specialty & Generic industry. Your money leaves India under the RBI's Liberalised Remittance Scheme and the shares are held in your own name at Interactive Brokers.
Do I need to buy a full Shenzhen Neptunus Interlong Bio-technique share?
Usually more than one, and not a fraction: many Hong Kong listings trade in board lots, so the smallest order is one lot rather than one share. At HK$0.09 a share, size the order by the lot, not by the share.
What tax do I pay in India when I sell Shenzhen Neptunus Interlong Bio-technique shares?
Hong Kong generally does not levy capital gains tax on non-resident individual investors for HKEX-listed stocks. In India, gains on shares held for more than 24 months are long-term and taxed at 12.5%, and gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate. Both are worked out in rupees at the HKD/INR rate on the day you bought and the day you sold, so the currency move is part of the gain. Paasa's capital-gains statement gives you the figures for your return.
Would my heirs owe estate tax on Shenzhen Neptunus Interlong Bio-technique shares?
Hong Kong has no estate duty. That is the source-country side; the shares themselves pass on like any other asset you hold in your own name.